Scope of Santaris, Isis Patent Suit Narrows – for Now
By Cormac Sheridan
Tuesday, September 25, 2012
Santaris Pharma A/S and Isis Pharmaceuticals Inc. both put a positive gloss on the latest twist in their ongoing patent litigation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.